Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.68 |
| ▸ | MAOA | P21397 | 4/20 | 0.68 |
| ▸ | NR4A2 | P43354 | 5/20 | 0.66 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | RXRA | P19793 | 1/20 | 0.52 |
| ▸ | RXRB | P28702 | 1/20 | 0.52 |
| ▸ | RXRG | P48443 | 1/20 | 0.52 |
| ▸ | HPD | P32754 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.49 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.49 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5605259 | 0.89 | SMPD1 (0.65) | MAOBMAOANR4A2SMPD1KMT2A | |
| SCHEMBL4200015 | 0.88 | MAOB (0.66) | MAOBMAOANR4A2SMPD1KMT2A | |
| SCHEMBL30678236 | 0.88 | MAOB (0.66) | MAOBMAOANR4A2SMPD1KMT2A | |
| SCHEMBL5604959 | 0.85 | SMPD1 (0.63) | MAOBMAOANR4A2SMPD1KMT2A | |
| SCHEMBL5744375 | 0.85 | SLC2A1 (0.54) | MAOBMAOANR4A2SMPD1KMT2A | |
| SCHEMBL1436284 | 0.81 | MAOB (1.00) | MAOBMAOANR4A2SMPD1KMT2A | |
| SCHEMBL7052037 | 0.80 | NR4A2 (1.00) | MAOBMAOANR4A2SMPD1KMT2A | |
| SCHEMBL25720168 | 0.80 | LMNA (0.50) | KMT2ARXRARXRBMEN1NPC1 | |
| SCHEMBL25720520 | 0.80 | FFAR1 (0.53) | MAOBMAOASMPD1KMT2AMRGPRX4 | |
| SCHEMBL5866349 | 0.80 | GPR132 (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1499577-B1 | 2-(2,6-DICHLOROPHENYL)-DIARYLIMIDAZOLES | HOFFMANN LA ROCHE (CH) | 2007-05-30 | — | — | EP | disclosed |
| US-6946471-B2 | 2-(2,6-Dichlorophenyl)-Diarylimidazoles | HOFFMANN-LA ROCHE INC. (US) | 2005-09-20 | — | — | US | disclosed |
| EP-1499577-A1 | 2-(2,6-DICHLOROPHENYL)-DIARYLIMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-26 | — | — | EP | disclosed |
| US-20040214874-A1 | 2-(2,6-Dichlorophenyl)-Diarylimidazoles | BRANDT MICHAEL | 2004-10-28 | — | — | US | disclosed |
| US-6790852-B2 | HETEROCYCLIC NITROGEN COMPOUNDS SUCH AS 2-(2,6-DICHLOROPHENYL) -4-(3-BROMOPHENYL)-5-(2-(3- HYDROXYPROPYLAMINO)PYRIMIDIN-4-YL) -N-H-IMIDAZOLE, USED AS TYROSINE KINASE INHIBITORS; ANTICARCINOGENIC OR ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. | 2004-09-14 | — | — | US | disclosed |
| US-20030199691-A1 | 2-(2,6-dichlorophenyl)-diarylimidazoles | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-23 | — | — | US | disclosed |
| WO-2003087026-A1 | 2-(2,6-DICHLOROPHENYL)-DIARYLIMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199691-A1 | 2-(2,6-dichlorophenyl)-diarylimidazoles | CYP2D6, CYP2F1, CYP1A2 | MAOB 414/4885MAOA 525/4885NR4A2 2261/4885 |
| US-20040214874-A1 | 2-(2,6-Dichlorophenyl)-Diarylimidazoles | CYP2D6, CYP1A2, CYP2F1 | MAOB 476/4885MAOA 600/4885NR4A2 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.